Health and Economic Impact of a Novel 3-Antigen Vaccine for the Prevention of Hepatitis B in Adults in Germany: A Cost-Effectiveness Analysis

Author(s)

Talbird S1, Graham J1, Anderson S1, Nossov M2, Beattie N2, Laíns Sousa C2, Rak A2, Masters III H2, Diaz-Mitoma F2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2VBI Vaccines Inc., Cambridge, MA, USA

OBJECTIVES: The novel 3-antigen hepatitis B vaccine was granted marketing authorization by the European Commission in April 2022. This analysis estimates the cost-effectiveness of the 3-antigen vaccine relative to the single-antigen vaccine to prevent hepatitis B virus (HBV) infection among adults in Germany.

METHODS: A cost-effectiveness model was developed using a combined decision tree and Markov structure to follow 100,000 adults over their remaining lifetimes after vaccination with either the 3-antigen or single-antigen vaccine. Seroprotection rates by dose were obtained from the pivotal, phase 3, head-to-head PROTECT trial (NCT03393754). Population demographics (Federal Statistics Office, 2021), HBV incidence (RKI, 2020), costs, and other parameters were obtained from published sources for Germany. Health and cost outcomes (2020 Euros) were discounted 3% annually and reported for the societal perspective for adults aged 18-44, 45-64, and ≥ 65 years; diabetic adults; and obese adults. One-way sensitivity and scenario analyses (≥ 100 mIU/ml seroprotection threshold) were conducted.

RESULTS: The 3-antigen vaccine resulted in fewer acute and chronic HBV infections, fewer complications and deaths, and more quality-adjusted life-years (QALYs) compared with the single-antigen vaccine due to higher seroprotection rates and faster onset of seroprotection. Reductions in HBV-related infections and costs were greatest in adults aged 18-44 years (−37% for 18-44 years; −27% for 45-64 years; −22% for ≥ 65 years; −18% for diabetic adults; −29% for obese adults). Given assumed price parity, the 3-antigen vaccine resulted in lower total costs and was the dominant strategy compared with single-antigen vaccine. The 3-antigen vaccine remained the dominant vaccination strategy in all scenarios conducted.

CONCLUSIONS: Compared with the single-antigen vaccine, the 3-antigen vaccine averted more infections, resulted in more QALYs, and had lower direct medical costs and total costs. The 3-antigen vaccine represents an additional meaningful tool for addressing the burden of hepatitis B among adults in Germany.

Conference/Value in Health Info

2022-11, ISPOR Europe 2022, Vienna, Austria

Value in Health, Volume 25, Issue 12S (December 2022)

Code

EE403

Topic

Economic Evaluation, Epidemiology & Public Health, Study Approaches

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis, Decision Modeling & Simulation, Public Health

Disease

STA: Vaccines

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×